Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.3.4 updated from v3.3.3; no visible changes to study details or site functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedDifference2%

- Check59 days agoChange DetectedPublication note wording changed to indicate publications are automatically filled from PubMed, and the Revision tag was updated to v3.3.2 (replacing v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded Tainan, Taiwan as a study site. Removed the Tainan City, Taiwan listing and the government-funding status notice from the page.SummaryDifference0.2%

- Check81 days agoChange DetectedNo significant changes were detected on the Study Details page for NCT03673501. The content, locations, and eligibility criteria appear unchanged.SummaryDifference0.2%

- Check109 days agoChange Detected- Updated version to v3.2.0 and removed the Gastrointestinal stromal tumor resource from Genetic and Rare Diseases Information Center. - Added a government funding lapse notice with operating-status guidance for users.SummaryDifference2%

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.